Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 4, 2012, Pages

  Karner, Charlotta ^a   Cates, Christopher J ^b  

^a BMJ   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; SALMETEROL; TIOTROPIUM BROMIDE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

ALL CAUSE MORTALITY; CAUSAL ATTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; AGED; MIDDLE AGED;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; ETHANOLAMINES; HUMANS; INDANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; SCOPOLAMINE DERIVATIVES;

EID: 84863841937     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008989.pub2     Document Type: Review

References (61)

1. Aaron SD, Vandemheen K, Ferguson D, FitzGerald M, Maltais F, Boureau J, et al.The Canadian optimal therapy of COPD trial: Design, organization and patient recruitment. Canadian Respiratory Journal 2004;11(8):581-5.
2. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al.Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.[see comment][summary for patients in Ann Intern Med. 2007 Apr 17;146(8):I12; PMID: 17310044]. Annals of Internal Medicine 2007;146(8):545-55.
3. Kaplan A. Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal 2007;16(4):258-60.
4. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al.Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63(11):962-7.
5. Roisman G. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique 2007;63(6):390-1.
6. A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease. www.novctrd.com. [: CQAB149B2341]
7. Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Combining once-daily bronchodilators In COPD: Indacaterol plus tiotropium versus tiotropium alone. American Journal of Respiratory and Critical Care Medicine. 2011, issue 183.
8. A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease. www.novctrd.com. [: CQAB149B2351]
9. Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Combining once-daily bronchodilators In COPD: Indacaterol plus tiotropium versus tiotropium alone. American Journal of Respiratory and Critical Care Medicine. 2011, issue 183.
10. Tashkin D, Varghese S. Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology. 2007; Vol. 119, issue 1 Suppl:S4 [13].
11. Tashkin D, Varghese S. The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12-week, multicenter, double-blind, placebo-controlled, trial. Chest. 2007; Vol. 132, issue 4:529a.
12. Tashkin DP. Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference, May 16-21, 2008, Toronto. 2008:A647[#F5].
13. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 2009;6(1):17-25.
14. Tashkin DP, Pearle JL, Varghese S. Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest. 2008; Vol. 134, issue 4:103002s.
15. Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al.Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal. 2006; Vol. 28, issue Suppl 50:440s [P2514].
16. Novartis . A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable Chronic Obstructive Pulmonary Disease. www.novctrd.com. [: CFOR258F2402]
17. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respiratory Medicine 2008;102(11):1511-20.
18. Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D, et al.Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal. 2006; Vol. 28, issue Suppl 50:429s [P2506].
19. Bateman ED, Hodder R, Miravitlles M, Lee A, Towse L, Serby C. A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life. European Respiratory Journal. 2001; Vol. 18, issue Suppl 33:26s.
20. Brusasco V, Menjoge SS, Kesten S. Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference. 2003:B024 Poster 420.
21. Di Marco F, Carlucci P, Ccarlucci P, Verga M, Mondoni M, Pistone A, et al.A single dose of formoterol (FOR) and tiotropium (TIO) reduce hyperinflation in COPD patients [Abstract]. European Respiratory Journal. 2003; Vol. 22, issue Suppl 45:Abstract No: [P1844].
22. Fujimoto K, Komatsu Y, Kanda S, Itou M, Yoshikawa S, Yasuo M, et al.Comparison of clinical efficacy of tiotropium and salmeterol for pulmonary function, air-trapping, exercise capacity, and HRQO in COPD [Abstract]. Respirology. 2007; Vol. 12, issue Suppl 4:A164.
23. Gross NJ, Paulson D, Kennedy D, Korducki L, Kesten S. A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract]. Respiratory Care. 2003; Vol. 48, issue 11:1081.
24. Jones CDS. The combined effect of tiotropium and formoterol on the functional status of patients with moderate-to-severe COPD [Dissertation]. CINAHL Accession Number: 2011033276//UMI Order AAI3408930 2010:144 p. [: 978-112-405-5602602]
25. Meyer T, Brand P, Reitmeir P, Scheuch G. Effect of formoterol, salbutamol and tiotropium bromide on the efficacy of lung clearance in patients with COPD [Abstract]. American Thoracic Society International Conference, May 16-21, 2008, Toronto. 2008:A646[#F1].
26. New J, Hanania N, Matovinovic E, Tashkin D. Adding nebulized formoterol to tiotropium treatment provides added benefits in pulmonary function, dyspnea and rescue medication use: a pooled analysis [Abstract]. American Thoracic Society International Conference, May 15-20, 2009, San Diego. 2009:A4541 [Poster #J51].
27. ten Hacken NH, van der Haart H, Grevink R, Thompson S, Roemer W, Postma DS. Bronchodilation improves endurance but not muscular efficiency in COPD [Abstract]. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA. 2007:Poster #M72.
28. Van Noord J, Aumann J, Janssens E, Mueller A, Cornelissen P. Relation between the aute response to salbutamol and long term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T=F) in COPD patients [abstract]. European Respiratory Journal. 2003; Vol. 22, issue Suppl 45:Abstract No: 153.
29. van Noord JA, Qumann J, Janssens E, Mueller A, Cornelissen PJ. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. American Thoracic Society 99th International Conference. 2003:B024 Poster 421.
30. van Noord JA, Smeets JJ, Otte A, Bindels H, Mueller A, Cornellissen PJG. The effect of tiotropium, salmeterol and it's combination on dynamic hyperinflation in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[B93] [Poster: 310].
31. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MMK, et al.Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD001104.pub2]
32. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2]
33. Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. Advances in Therapy. 2009/07/18 2009; Vol. 26, issue 7:691-9. [0741-238X: (Print)]
34. Beier J, Beeh KM. Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol. International Journal of Chronic Obstructive Pulmonary Disease. 2011/08/05 2011; Vol. 6:237-43. [1178-2005: (Electronic)]
35. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine 2008;102(2):173-88. [0954-6111: (Print)]
36. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356(8):775-89.
37. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics 2010;23(4):257-67.
38. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2009/07/14 2010; Vol. 137, issue 1:20-30. [1931-3543: (Electronic)]
39. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD009552.pub2]
40. Effing T, Monninkhof EM, van der Valk PDLPM, Zielhuis GA, Walters EH, van der Palen J, et al.Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2]
41. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. http://www.goldcopd.com 2009.
42. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, Available from www.cochrane-handbook.org, 2008.
43. Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal 2010;40(5):364-71.
44. Johnson M. The beta-adrenoceptor. American Journal of Respiratory and Critical Care Medicine 1998;158(5 Pt 3):S146-53.
45. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2]
46. Lacasse Y, Goldstein R, Lasserson Toby J, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2]
47. Moen MD. Indacaterol: in chronic obstructive pulmonary disease. Drugs. 2010/11/18 2010; Vol. 70, issue 17:2269-80. [0012-6667: (Print)]
48. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al.Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63(11):962-7.
49. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, Costing report, Implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English.
50. Proskocil BJ, Fryer AD. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proceedings of the American Thoracic Society 2005;2(4):305-10; discussion 311-2.
51. The Nordic Cochrane Centre; Cochrane Collaboration. Review Manager (RevMan) Version 5. Copenhagen: The Nordic Cochrane Centre; Cochrane Collaboration, 2008.
52. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of Long-Acting β-Agonists in Stable COPD*. Chest 2008;133(5):1079-87.
53. Jones P. St George's Respiratory Questionnaire for COPD Patients (SGRQ-C). St George's, University of London 2008.
54. Singh S. Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD. Evidence Based Medicine 2009;14(2):42-3.
55. Tanaka Y, Horinouchi T, Koike K. New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clinical and Experimental Pharmacology and Physiology 2005;32(7):503-14.
56. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal Medicine 2008;359(15):1543-54.
57. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respiratory Medicine 2008;102(4):479-87.
58. van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck O. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD002999]
59. Wallukat G. The beta-adrenergic receptors. Herz 2002;27(7):683-90.
60. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2]
61. World Health Organization. Chronic Respiratory Diseases. www.who.int.